Astellas (ALPMF) and Audentes Therapeutics (BOLD) merger information including expected completion date and offer price are displayed in the deal information table below.
This deal was successfully consummated on January 14, 2020
| Merger Details | Value |
|---|---|
| Acquisition Target Stock Name | Audentes Therapeutics |
| Acquisition Target Stock Ticker | BOLD |
| Acquirer Stock Name | Astellas |
| Announcement Date | December 3, 2019 |
| Expected Completion Date | March 31, 2020 |
| Deal Value | $3bn |
| Offer Price | $60.00 |
| Payment Method | All Cash Deal, Tender Offer |
| Actual Completion Date | January 14, 2020 |
The major Audentes Therapeutics (BOLD) merger news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the Astellas (ALPMF) takeover of Audentes Therapeutics (BOLD) and trade the merger arbitrage spread. Following the acquisition news and events section, there is in-depth company profile. For more proprietary Merger Arbitrage Limited content and analysis on the Audentes Therapeutics (BOLD) buyout, follow this link Audentes Therapeutics (BOLD). Change the ticker symbol as required to access news and acquisition details of additional merger stocks. The current merger arbitrage spread is available on our Spread Tracker page.
Receive instant FREE access to constantly updated BOLD news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates.
Traders can also review similar deals by simply entering a ticker symbol into the search box in the menu bar above or click on an acquisition target stock ticker in the tag cloud at the foot of this article. For broader takeover news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
Audentes Therapeutics (NASDAQ: BOLD) Merger - Acquisition News and Events
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
